Xceleron welcomes publication by The Center for Drug Evaluation and Research (CDER) at the FDA of a guidance document on “Exploratory IND Studies"[1] presenting its views on a more flexible approach to early Phase I clinical studies.
Xceleron welcomes publication by The Center for Drug Evaluation and Research (CDER) at the FDA of a guidance document on “Exploratory IND Studies"[1] presenting its views on a more flexible approach to early Phase I clinical studies.